氟哌噻吨美利曲辛片治疗伴郁抑性精神障碍灼口综合征的临床疗效

The efficacy of flupentixol and melitracen tablets in the treatment of burning mouth syndrome

观察氟哌噻吨美利曲辛片(黛力新)对灼口综合征(BMS)的干预效应。纳入120例确诊的BMS患者,随机分成2组,试验组60人,服用氟哌噻吨美利曲辛片,每次1片,1次/d,晨服,连服6周;对照组60人服用谷维素,每次1粒,3次/d,连服6周。治疗前后观察患者的疼痛程度和发生频率。试验组痊愈32例,显效21例,有效6例,无效1例,总改善率80.5%;对照组改善率21.2%,差异有显著性(P<0.01)。灼口综合征是心因性疾病,用抗抑郁药物黛力新治疗效果好。

120 patients with burning mouth syndrome were randomly and equally divided into two groups（n=60）： Flupentixol and melitracen（deanxit） treatment group and oryzanol group（control）.Deanxit was given at 20 mg daily for 6 consecutive weeks in deanxit group and oryzanol tablets at a dose of 3 tablets daily for 6 consecutive weeks in control group.Therapeutic effect was evaluated by pain rating.A total effective rate of 80.5% was obtained in deanxit group and 21.2% in the control（P〈0.01）.Flupentixol and melitracen tablet is effective in the treatment of burning mouth syndrome.